LLY - ELI LILLY & Co
1001.35
-7.040 -0.703%
Share volume: 1,659,734
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$1,008.39
-7.04
-0.01%
Fundamental analysis
59%
Profitability
75%
Dept financing
22%
Liquidity
37%
Performance
57%
Performance
5 Days
1.11%
1 Month
-1.37%
3 Months
-0.80%
6 Months
32.40%
1 Year
21.51%
2 Year
36.35%
Key data
Stock price
$1,001.35
DAY RANGE
$994.00 - $1,012.00
52 WEEK RANGE
$623.78 - $1,133.95
52 WEEK CHANGE
$21.84
DIVIDEND
$1.73
EX-DIVIDEND DATE
02-13-2026
NEXT EARNINGS DATE
08-07-2025
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news